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B PD is a prevalent and serious mental disorder characterized by a pervasive pattern of instability in interpersonal relationships, affect regulation, and self-image, as well as marked impulsivity. 1 It is associated with impaired social and occupational functioning and high rates of medical and psychiatric services use. [2] [3] [4] According to clinical data and APA guidelines, the treatment options of BPD include both pharmacological and psychotherapeutic interventions. [5] [6] [7] [8] [9] To date, different models of psychotherapy have been tested for BPD in studies of single or combined therapy. [10] [11] [12] [13] The most extensively tested are: psychodynamic psychotherapy, [14] [15] [16] [17] dialectical behaviour therapy, [18] [19] [20] [21] [22] cognitive therapy [23] [24] [25] and IPT. Concerning IPT, although it was initially developed by Klerman et al 26 to treat major depression, some investigators have successfully extended its indications to other psychiatric disorders. [27] [28] [29] [30] [31] [32] [33] In a recent pilot study, Markowitz 34 and Markowitz et al 35 proposed an adaptation of IPT to the treatment of patients with BPD. IPT-BPD, designed by Markowitz 34 and Markowitz et al, 35 departs from the standard acute treatment of major depression to suit the needs of this particular and severe population of patients. Features of adaptation involve: different conceptualization of the disorder (BPD is defined as a mood-inflicted chronic illness similar to dysthymic disorder but with sporadic outbursts of anger); prolonged length of treatment (a first acute phase of 18 IPT sessions and a continuation phase of 16 sessions, up to 34 IPT sessions over 8 months); and flexibility of setting (a 10-minute telephone contact once a week is provided) to handle crises and minimize the risk of therapeutic ruptures.
In previous studies performed by our group, 13, 36 IPT has been efficaciously used to treat major depression in patients with concomitant BPD. However, data on treatment of core BPD symptoms with IPT are sparse. Initial data was derived from a comparison controlled study with the relationship management therapy 37 and from a case series by Markowitz 34 and Markowitz et al. 35 Our study performed IPT-BPD 34 on patients with BPD and without concomitant Axis I disorders, comparing combined treatment (IPT-BPD plus a selective serotonergic reuptake inhibitor, fluoxetine) with single pharmacotherapy (fluoxetine). Drug therapy was provided to all patients, according to the treatment algorithm proposed by Soloff. 38 Fluoxetine was chosen because it is considered a safe and well-tolerated AD, evaluated in studies of major depression and BDP, 8, [39] [40] [41] [42] [43] and recommended by APA treatment guidelines. 5, 6 Methods Participants were recruited from patients attending the Service for Personality Disorders of the Unit of Psychiatry 1, Department of Neurosciences, University of Turin, Italy, from January to December 2007.
Consecutive outpatients who received a DSM-IV-TR 1 diagnosis of BPD were included. We excluded people with a lifetime diagnosis of: delirium, dementia, amnestic disorder, or other cognitive disorders; schizophrenia or other psychotic disorders; and biplar disorder. Concomitant diagnoses of Axis I or II disorders were also considered exclusion criteria.
Diagnoses were made by an expert clinician and were confirmed using the Structured Clinical Interview for DSM-IV Axis I and II disorders. 44, 45 Patients of childbearing age were excluded if they were not using an adequate method of birth control (according to the judgment of the clinician).
Patients were also excluded if receiving psychotropic drugs in the last 2 months and (or) psychotherapy in the last 6 months.
Written informed consent was obtained from all patients prior to their participation. We followed the Declaration of Helsinki guidelines and received the ethics board approval.
Patients were randomly allocated to 1 of the 2 treatment cells: pharmacotherapy or combined therapy. Randomization was performed using the web program Research Randomizer version 3.0 (Urbaniak and Plous, Social Psychology Network, Wesleyan University, Middletown, CT). Pharmacotherapy consisted of fluoxetine 20 to 40 mg per day plus clinical management. The fluoxetine-only patients received the usual treatment approach of patients attending the Service for Personality Disorders. A visit lasting 15 to 20 minutes was provided every 2 weeks, dealing with clinical issues. Combined therapy provided fluoxetine 20 to 40 mg per day plus IPT adapted to BPD according to Markowitz's model (IPT-BPD). A complete description of adaptation of IPT characteristics and techniques to BPD was provided. 34 All patients received fluoxetine initially at a fixed dosage of 20 mg daily, with the opportunity to increase the dosage to 40 mg daily beginning in week 2, depending on clinical judgment. The pharmaco-and psychotherapy started at the same time. Patients in the IPT-BPD group were treated by a psychotherapist who was not the psychiatrist prescribing medication and who had at least 5 years of experience practicing IPT. This criterion was used in previous investigations of psychotherapy and was chosen in the 2 studies of IPT published by our group. 13, 36 Patients underwent their respective treatments for 32 weeks.
All patients were assessed at baseline (T0), week 16 (T1), and week 32 (T2) with the following instruments: a semistructured interview to assess demographic and clinical characteristics (age, sex, marital status, employment, education, and previous hospitalization); the severity and improvement items of the CGI to assess the level of global symptomatology 46 ; the HDRS and HARS 47, 48 ; the SOFAS, 49 a self-report scale that assesses the social and occupational level of functioning; the SAT-P, 50 a self-administered questionnaire consisting of 32 scales that provide a satisfaction profile in daily life and can be considered an indicator of subjective quality of life (it considers 5 different factors: psychological functioning; physical functioning; work; sleep, food, and free time; and social functioning; this questionnaire allows analysis of patients' perception of their level of functioning and treatment benefits); and the BPD-SI, a semistructured clinical interview assessing the frequency and severity of manifestations of BDP. This interview consists of 8 items scored on a 10-point frequency scale (0 = never; 10 = daily) including abandonment, interpersonal relationships, impulsivity, parasuicidal behaviour, affective instability, emptiness, outbursts of anger, dissociation and paranoid ideation, and 1 item scored on a 4-point severity scale concerning identity. The BPD-SI showed excellent reliability coefficients and good validity indices. 51 The assessments were performed by an investigator who was blind to the treatment methods. Criteria for response were a decrease of 50% or more of BPD-SI total score, with a score of 1 (very much improved) or 2 (much improved) on the improvement item of the CGI. A decrease of 50% or more of the total score of the main symptom rating scale (BPD-SI in our study) was considered a criterion of response in several recent trials. [52] [53] [54] The Dosage Record Treatment Emergent Symptom Scale 46 was used to collect adverse effects.
We performed statistical analyses using the univariate GLM to calculate the effects of 2 factors (that is, the duration and the type of treatment) on each assessment scale score.
Pearson chi-square test was used to compare the frequency of adverse events in the 2 treatment subgroups. P values were considered significant when P = 0.05.
Results
Fifty-five patients were enrolled in our study. Twenty-eight patients received single pharmacotherapy, the remaining 27 received combined therapy with IPT-BPD. Baseline characteristics of the 2 groups are reported in Table 1 . Owing to noncompliance, 11 patients (20%) discontinued treatment during the first 4 weeks. Among these patients, 5 were in the combined therapy group and 6 in the pharmacotherapy group. We performed statistical analysis of outcome measures on the 44 patients (that is, 22 patients in each group) who completed the 32 weeks of treatment. At the end point, 45 .5% (n = 10) of the patients treated with pharmacotherapy and 54.5% (n = 12) of patients treated with combined therapy fulfilled criteria for response. Statistical comparison with the Pearson chi-square test did not show a significant difference (P = 0.55).
Results of the univariate GLM performed on the CGI-S, the HDRS, the HARS, and the SOFAS are presented in Table 2 .
Concerning the CGI-S, the HDRS, and the SOFAS only time factor had a significant effect (P < 0.001): both treatments were efficacious on global and depressive symptoms.
Both time and treatment factors showed a significant effect (respectively, P < 0.001 and P = 0.006) on the HARS: it means that both treatments were efficacious, but combined therapy was superior to single pharmacotherapy in improving anxious symptoms. Table 3 presents the results of the GLM calculated for the 5 factors of the SAT-P. Concerning the 3 factors physical functioning; work; and sleep, food, and free time, only the time factor had a significant effect, indicating no difference of efficacy between the 2 treatment arms. Both the treatment factor (P = 0.003; P = 0.008) and the interaction between time and treatment (P = 0.01; P = 0.03) had an effect on the 2 factors-psychological functioning and social functioning.
These data indicate that combined therapy was more efficacious than pharmacotherapy and the differences between treatments increased with the duration of therapy.
Results of the univariate GLM calculated for the total score and the 9 domains of the BPD-SI are described in Tables 4 and  5 . Neither the time factor, nor the treatment factor had effects on the domains: abandonment, parasuicidal behaviour, paranoid ideation, and identity; the 2 treatment options could not induce a change in these domains. Only the time factor had a significant effect on the BPD-SI total score and on the domains: outbursts of anger (P < 0.001) and emptiness (P < 0.001). Time factor (T), treatment factor (t), and Time × treatment interaction (T × t) had a significant effect on the following items: interpersonal relationships (P "T" < 0.001; P "t"= 0.009; P "T × t" = 0.001), impulsivity (P "T"< 0.001; P "t"= 0.01; P "T × t" < 0.001), and affective instability (P "T" < 0.001; P "t" = 0.02; P "T × t" = 0.007). These results indicate that combined therapy had more of an impact on these areas than single pharmacotherapy and that the difference increased during the period of the trial.
Treatment-emergent adverse events in the whole sample of 55 BPD patients were mild to moderate in severity and no patients dropped out due to adverse events. The most common effects were headache (n = 9; 16.36%), nausea (n = 8; 14.55%), dyspepsia (n = 8; 14.55%), and insomnia (n = 6; 10.91%). No statistical differences were found between the 2 treatment subgroups for the frequency of these adverse events.
Discussion
Our study tested the IPT adapted to BPD according to Markowitz's model in a sample of BPD patients without Axis I or II concomitant diagnoses. The IPT could be a good approach to BPD treatment, given the prominent interpersonal problems related to this personality disorder. 55 Moreover, BPD has a frequent comorbidity and presents clinical similarities with mood disorders that were the original specific indication of IPT. We decided to include only pure BPD patients to examine the effects of IPT-BPD on the core symptoms of this personality disorder, without the interference of comorbid psychopathology. With the aim to define the contribution of this type of psychotherapy to BPD treatment, we compared the efficacy of IPT-BPD associated with pharmacotherapy with single pharmacotherapy. All participants were treated with medications, according to the treatment algorithm developed by Soloff. 38 They received fluoxetine because it is considered a safe and well-tolerated AD, tested in many studies of major depression and a few studies of BDP, 8, [39] [40] [41] [42] [43] and recommended by APA treatment guidelines for BPD. 5, 6 In a previous investigation, 13 we found that combined treatment with IPT and fluoxetine was superior to single pharmacotherapy in treating depressive symptoms of patients with BPD and a concomitant major depressive episode. Only very sparse data were available on effects of IPT in treating core symptoms of pure BPD patients. 35, 37 Our study results indicated that the 2 treatment options (that is, fluoxetine plus IPT-BPD, compared with fluoxetine plus clinical management) are both efficacious on pure BPD patients. In particular, they did not differ significantly in rates of response and improvement of global psychopathology. On the contrary, significant differences between the 2 subgroups were found in measures of anxiety symptoms, factors related to subjective quality of life, and core symptoms of BPD.
In particular, our results showed that combined therapy with IPT-BPD was superior to single pharmacotherapy in reducing anxious symptoms as measured by the HARS. It is possible to hypothesize that this difference depends on a nonspecific effect of psychotherapy 35, 56 : most forms of psychotherapy produce a similar result providing support and helping patients to feel understood. Moreover, combined therapy was found to be significantly superior to single pharmacotherapy in improving the psychological and social functioning as measured by the SAT-P scale for subjective quality of life. In several previous studies, IPT has been shown to improve interpersonal functioning in patients with mood and anxiety disorders. 28, 31, [57] [58] [59] [60] [61] During IPT-BPD sessions, patients who have been feeling impotent and out of control are ensured to adopt new skills to solve their interpersonal problems, and success experiences are emphasized in an optimistic way that reinforce a sense of better functioning. Patients learn to feel in control of their emotions and their interactions with others; handling relationships more functionally can improve a patient's quality of life.
Concerning BPD symptoms, combined therapy with IPT-BPD was found to be more efficacious than pharmacotherapy on interpersonal relationships, impulsive behaviours, and affective instability, as indicated by BPD-SI items. IPT-BPD had positive effects on 3 symptom domains that approximately correspond to the 3 dimensions of BPD identified by factorial analyses. [62] [63] [64] [65] Our findings are approximately concordant with the sparse comparable data in literature. In a trial reported by Markowitz et al, 35 Gillies and colleagues adapted IPT to BPD patients, proposing a fifth interpersonal problematic area called self-image, and treated 13 patients (among them, 1 with comorbid major depression) in 12 weekly sessions: overall pathology and self-reported symptoms declined.
Markowitz et al 35 performed a pilot trial of IPT-BPD on 8 subjects with BPD and comorbid mood and other personality disorders. The 5 patients who completed the 8 months of treatment no longer fulfilled DSM-IV diagnostic criteria for BPD. They showed a significant improvement on the CGI, HDRS, Social Adjustment Scale, and Symptom Checklist-90. 66 The results of our study are very similar to Markowitz and colleague's 35 findings, even though we found that the improvement of depressive symptoms did not significantly differ in the 2 groups of treatment. It could be due to the rather low HDRS scores in our sample.
A limitation of our study is that excluding Axis I comorbidity may imply that our population has different clinical characteristics from patients treated in clinical practice.
In addition, assessment of the efficacy of psychotherapy should be completed with more specific instruments. We know that IPT produces its effects on interpersonal difficulties of BPD. Gunderson 52 has recently proposed that the specific BPD disturbed interpersonal style has 2 underlying psychological endophenotypes: mentalization failures and rejection sensitivity. The specific effect of psychotherapy on these endophenotypes should be investigated with appropriate assessment instruments to better define the mechanisms of action of IPT on BPD psychopathology.
Another limitation of this initial trial of IPT-BPD is that intention-to-treat analyses were not included.
In conclusion, our findings suggest that the IPT-BPD proposed by Markowitz and colleagues 35 could be an efficacious model of intervention that responds to the growing demand for manualized and time-limited treatment of BPD. As consistently found in the literature, other models of psychotherapy can be effective, too. In particular, dialectical behaviour therapy has proven efficacious in reducing suicidal behaviours and improving control in self-destructive BPD patients, through learning emotion-regulation skills in the validating environment of the treatment. [18] [19] [20] [21] [22] 67 A comparison of the effects of IPT-BPD with other models of psychotherapy would provide useful data, to identify the optimal matching of therapeutic models and techniques with selected clinical characteristics of BPD.
